Haesong Park, MD, of the Dana‑Farber Cancer Institute (IMAGE)

Alliance for Clinical Trials in Oncology

Haesong Park, MD, of the Dana‑Farber Cancer Institute

Caption

Alliance A022102: mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Haesong Park, MD, of the Dana‑Farber Cancer Institute, is evaluating treatment options for people with metastatic HER2‑negative esophageal, gastroesophageal junction, and gastric cancers. The phase III trial compares two chemotherapy regimens, mFOLFIRINOX and mFOLFOX, with or without the immunotherapy drug nivolumab. The goal is to understand which regimen (or combination) offers the best outcomes for patients.

Credit

Dana-Farber Cancer Institute

Usage Restrictions

none

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.